Drug
Dersimelagon clinical trials
Also written MT-7117.
- studies test it
- 13
- open now
- 0
- in phase 3
- 3
- first study started
- 2016
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 2
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Mitsubishi Tanabe Pharma America Inc. (6) · Tanabe Pharma America, Inc. (5) · Tanabe Pharma Corporation (1) · Mitsubishi Tanabe Pharma Corporation (1)
Studies
Open first, then newest update. How each study uses dersimelagon is read from its arms, and is right about nine times in ten.
Testing it · 13
- Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Active, not recruitingPhase 3Tanabe Pharma America, Inc.NCT05005975Written as MT-7117
- INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPCompletedPhase 3Tanabe Pharma America, Inc.NCT06144840Written as Dersimelagon
- The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.CompletedPhase 1Tanabe Pharma CorporationNCT06994286Written as MT-7117
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic ProtoporphyriaCompletedPhase 2Tanabe Pharma America, Inc.NCT03520036Written as MT-7117 low dose
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic SclerosisCompletedPhase 2Tanabe Pharma America, Inc.NCT04440592Written as MT-7117
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked ProtoporphyriaCompletedPhase 3Tanabe Pharma America, Inc.NCT04402489Written as MT-7117 Low Dose
- Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic FunctionCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT04116476Written as MT-7117
- Mass Balance Study With MT-7117CompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT03503266Written as [14C] MT-7117
- Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy SubjectsCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT05241535Written as MT-7117
- Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump InhibitorCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT03688022Written as MT-7117
- PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal FunctionCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT04656795Written as MT-7117
- Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy SubjectsCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT04793295Written as MT-7117
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy SubjectsCompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02834442Written as MT-7117
Codes
What other systems call dersimelagon · ClinicalTrials.gg INT014306
- UNII (FDA) 1CWH5SV4G2DERSIMELAGONOne source FDA
- NCI Thesaurus C166490DersimelagonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1CWH5SV4G2 | DERSIMELAGON | One source FDA |
| NCI Thesaurus | C166490 | Dersimelagon | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.